von Willebrand Factor/VWF Antibody (GMA-022): sc-65973
- von Willebrand Factor/VWF Antibody (GMA-022) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against VWF of human origin
- recommended for detection of VWF of human origin by WB and IP
- See von Willebrand Factor/VWF (C-12): sc-365712 for von Willebrand Factor/VWF antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for von Willebrand Factor/VWF Antibody (GMA-022). This work is in progress.
QUICK LINKS
SEE ALSO...
VWF Antibody (GMA-022) is a mouse monoclonal IgG1 antibody engineered to target von Willebrand factor (VWF) protein of human origin with exceptional precision, making anti-VWF antibody (GMA-022) an invaluable tool for applications such as western blotting (WB) and immunoprecipitation (IP). VWF is a critical multimeric glycoprotein predominantly synthesized in endothelial cells and megakaryocytes, where VWF is stored in Weibel-Palade bodies and platelet alpha granules, respectively. Upon vascular injury, VWF is rapidly released into the plasma, where VWF mediates platelet adhesion and aggregation by binding to glycoprotein Ib (GPIb) receptors on platelets and to exposed collagen in the subendothelial matrix, thereby initiating the clotting cascade. A key feature of VWF′s functionality is post-translational modifications, which include glycosylation, propeptide cleavage, and the formation of intersubunit disulfide bonds. Glycosylation is essential for proper folding, stability, and multimerization of VWF, influencing interaction with other coagulation factors and cellular receptors. Propeptide cleavage by metalloprotease ADAMTS13 is crucial for regulating the size and activity of VWF multimers, preventing excessive platelet aggregation and ensuring hemostatic balance. Additionally, the formation of intersubunit disulfide bonds is vital for maintaining structural integrity and multimeric state of VWF, which directly impacts ability to function effectively in hemostasis. Defects or aberrant post-translational modifications of VWF can lead to von Willebrand disease, the most common inherited bleeding disorder, characterized by impaired blood clotting and excessive bleeding. VWF monoclonal antibody (GMA-022) supports advanced research into molecular mechanisms underlying blood coagulation, pathophysiology of bleeding disorders, and development of targeted therapeutic interventions.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
von Willebrand Factor/VWF Antibody (GMA-022) | sc-65973 | 100 µg/ml | $316.00 |